Immunohistochemical determination of p53 protein does not predict clinicalresponse in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination
S. Cascinu et al., Immunohistochemical determination of p53 protein does not predict clinicalresponse in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination, ANN ONCOL, 11(8), 2000, pp. 1053-1056
Background: We assessed the hypothesis that a compromised p53 function coul
d account for the non response of colon cancer patients with low thymidylat
e synthase (TS) expression receiving a bolus 5-fluorouracil (5-FU)-leucovor
in (LV) combination.
Patients and methods: The study population consisted of 41 patients with un
resectable metastatic colon cancer, homogeneosuly, treated with bolus 5-FU
and LV.
Results: Twenty-seven patients (66%) showed high levels of TS expression. T
he difference in the proportion of objective responses between patients wit
h low (CR + PR: 7 of 14, 50%) and high (CR + PR: 0 of 27) TS levels was sta
tistically significant (P = 0.0001, chi-square test). p53 nuclear overexpre
ssion was found in 27 of 41 patients (66%). No differences were observed in
p53 overexpression in patients with high (66%) or low (66%) TS expression.
p53 status was not found to be associated with response even in patients w
ith low TS expression.
Conclusions: p53 status measured by immunohistochemistry does not seem to b
e useful to identify unresponsive patients with low TS expression.